Skip to main content

Table 5 Recommendations on the use of calcitonin gene-related peptide monoclonal antibodies for the prevention of episodic and chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Setting Drug Recommendation Quality of evidence Strength of the recommendation
Migraine prevention in patients with episodic migraine Eptinezumab 1000 mg quarterly Suggested LOW ↑? Weak
Erenumab 70 mg monthly Recommended HIGH ↑↑ Strong
Erenumab 140 mg monthly Recommended MEDIUM ↑↑Strong
Fremanezumab 225 mg monthly Recommended HIGH ↑↑ Strong
Fremanezumab 675 mg quarterly Recommended MEDIUM ↑↑Strong
Galcanezumab 240 mg loading dose + 120 mg monthly Recommended HIGH ↑↑ Strong
Galcanezumab 240 mg monthly Recommended HIGH ↑↑ Strong
Migraine prevention in patients with chronic migraine Erenumab 70 mg monthly Recommended MEDIUM ↑↑Strong
Erenumab 140 mg monthly Recommended MEDIUM ↑↑Strong
Fremanezumab 675 mg quarterly Recommended MEDIUM ↑↑Strong
Fremanezumab 675 mg loading dose + 225 mg monthly Recommended HIGH ↑↑ Strong
Galcanezumab 240 mg loading dose + 120 mg monthly Recommended MEDIUM ↑↑Strong
Galcanezumab 240 mg monthly Recommended MEDIUM ↑↑Strong
  1. Symbols depict the strength of the recommendation according to the GRADE system. The quality of evidence for the Galcanezumab study was changed from medium to high